As part of our commitment to elevate education around idiopathic #hypersomnia (IH), we’ve partnered with Medscape Medical Affairs to launch the Hypersomnia Hub. This online HCP resource includes informative content from expert clinicians and researchers highlighting clinical features, diagnostic criteria and clinical comorbidities in IH. Learn more here: https://wb.md/3AHCqDn
Über uns
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
- Website
-
http://www.jazzpharma.com
External link for Jazz Pharmaceuticals
- Industrie
- Pharmaceutical Manufacturing
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Dublin
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2003
- Spezialitäten
- Biopharmaceutical , innovation, research and development , great place to work, neuroscience , epilepsy, sleep disorders, oncology, and hematology
Standorte
Employees at Jazz Pharmaceuticals
Aktualisierungen
-
Biliary tract cancer (BTC) is composed of several different types of tumors, each with distinct characteristics that differ based on where they are located within the liver, gallbladder and biliary tract. We are focused on researching possible treatments for BTC, including one targeting a protein known as HER2, which impacts how the cancer grows and spreads. Learn more about BTC on our Pioneering Pathways page: https://bit.ly/3YVF4iT
-
"Don't be afraid to challenge yourself, think outside the box, challenge those around you. But most importantly don't be afraid to be you." Along with a strong, patient-focused culture, our team is defined by individuals who aren't afraid to be themselves and strive to embrace their unique skillsets. Our Associate Director, Alliance Management, Lauren Griffey, CA-AM, shares her tips and advice for how to gain confidence when going through the Jazz hiring process. Explore our career opportunities here: https://bit.ly/3YUONGi
-
Idiopathic hypersomnia (IH), a rare sleep disorder, can often be difficult to diagnose. In order for individuals to receive the most appropriate care, it’s important to know how this disorder differs from other common sleep conditions, like narcolepsy. Hear more from Dr. Richard Bogan, M.D., FCCP, FAASM in an installment in our Awakened Awareness series on some of the major differences between IH and narcolepsy.
-
This Biliary tract cancer (BTC) is typically aggressive and can pose significant challenges for people impacted, particularly in cases with HER2 overexpression. To help address this, we are pioneering a treatment approach that explores a novel bispecific antibody designed to target HER2-positive BTC with multiple mechanisms of action.
-
We are focused on developing treatments for difficult-to-treat cancers – including gastroesophageal adenocarcinoma (GEA). Although this cancer is increasingly common, new treatment options for HER2-positive GEA are still needed. Learn how we are exploring innovative HER2-targeted therapies: https://bit.ly/3YHSb7f
-
-
Through our patient-centered research and development programs, we are leveraging data and analytics to unlock a deeper understanding of patient experiences. We strive to engage and actively listen, incorporating their insights into all our decision-making processes. Our 2023 Corporate Sustainability and Social Impact (CSSI) report highlights our authentic partnerships and positive patient outcomes across our key therapeutic areas. Read the report here: https://bit.ly/4fTQNoe
-
Our EVP and Chief People Officer, Heidi Manna was a guest on the #DigitalHRLeaders podcast and spoke to David Green 🇺🇦 about employee experience, people and culture at Jazz. Heidi talked about the importance of authentic employee listening and how it has shaped the way we create solutions within the organization, including the creation of our flexible working model, Jazz Remix, which leverages a mix of virtual and in person collaboration to successfully deliver against our objectives: https://bit.ly/3WyH9hZ #GreatPlacetoWork
-
Today we recognize #WorldLungCancerDay and the impacts of #lungcancer, which affects millions of people worldwide every year. In particular, small cell lung cancer (#SCLC) brings a unique set of challenges to patients given it is often diagnosed at a late stage. We are committed to providing information and resources to patients with difficult-to-treat cancers like SCLC to help them navigate treatment on their own terms so they can live their lives more fully. Learn more on the Nothing Small About It website: https://lnkd.in/e6dt5Nay
-
Jazz announces second quarter 2024 financial results: https://bit.ly/4c9xNyI